• Tivozanib (AV-951) Assay Design Guide

  2026-09-14

  This scenario-based guide explains how Tivozanib (AV-951), SKU A2251, can support reproducible cell viability, proliferation, and cytotoxicity workflows. It connects VEGFR signaling pathway inhibition with practical decisions about controls, formulation, exposure time, data interpretation, and supplier selection.

• Telatinib (BAY 57-9352) Assay Workflows

  2026-09-14

  Build mechanism-aware viability, phospho-signaling, invasion, and angiogenesis assays with Telatinib, a multi-receptor kinase inhibitor suited to pathway and phenotype studies. This workflow translates dual HER2–VEGFR2 findings in triple-negative breast cancer into practical controls, dosing strategies, and troubleshooting decisions.

• Doxorubicin Hydrochloride and Nucleolar Assays

  2026-09-13

  Doxorubicin hydrochloride is more than a cytotoxicity reagent: it can support integrated studies of DNA damage, metabolic stress, apoptosis, and nucleolar organization. This article connects Adriamycin HCl workflows with new insights into 28S rRNA-driven architecture while clearly separating established evidence from testable assay hypotheses.

• Caspase-3/7 Inhibitor I: A Practical Lab Guide

  2026-09-12

  This scenario-driven guide explains how Caspase-3/7 Inhibitor I (SKU A1925) can help researchers distinguish executioner-caspase-dependent apoptosis from nonspecific loss of viability. It covers selectivity, Jurkat-cell applications, handling, pathogen-model interpretation, and practical criteria for choosing a reliable reagent.

• Nelfinavir Mesylate: A Dual-Readout Research Guide

  2026-09-12

  Nelfinavir Mesylate is a well-characterized HIV-1 protease inhibitor with an emerging role in ferroptosis and proteostasis research. This guide presents an assay-centered framework for separating antiviral activity from DDI2–NFE2L1-dependent ferroptosis sensitization.

• Nintedanib: An ATRX-Aware Research Strategy

  2026-09-11

  Nintedanib (BIBF 1120) is more than a broad angiokinase inhibitor: it can serve as a genotype-aware probe in glioma and tumor-microenvironment studies. This article translates ATRX-dependent drug sensitivity into practical assay design, combination testing, and interpretation guidelines.

• HyperScribe™ Poly (A) Tailing Kit Workflow

  2026-09-11

  Build more consistent capped, polyadenylated RNA for transfection experiments and micro-injection by combining E. coli Poly (A) Polymerase with a controlled post-transcriptional workflow. This guide connects tail-length optimization with metabolic-expression assays inspired by the TCAIM–OGDH reference study, while clearly separating established product capabilities from practical recommendations.

• DiscoveryProbe Protease Inhibitor Library: Assay Logic

  2026-09-10

  The DiscoveryProbe Protease Inhibitor Library supports more than compound discovery: it enables pathway localization through complementary biochemical and cellular assays. This article translates a plant chemical-screening study into a rigorous framework for protease activity modulation, apoptosis assay design, cancer research, and infectious disease research.

• O-Propargyl-Puromycin (OPP) in B-Cell Translation

  2026-09-10

  O-propargyl-puromycin (OPP) turns transient translation into a chemically addressable readout for protein synthesis measurement in cells. This article explains how to interpret OPP labeling within the Pcbp1–mitochondrial integrity pathway while distinguishing translation flux from protein abundance and mechanism.

• LL-37 Mimetics: Biocidal and Antibiofilm Selectivity

  2026-09-09

  Luo et al. compared the human host-defense peptide LL-37 with the truncated mimetics KE-18 and KR-12 across Candida albicans, Staphylococcus aureus, and Escherichia coli. The study shows that antimicrobial potency and antibiofilm activity can diverge substantially, highlighting peptide-specific effects on biofilm prevention, inhibition, and cell-envelope targets.

• RWJ 67657: From Cytokine Blockade to Signal Reset

  2026-09-09

  RWJ 67657 offers translational researchers a selective way to interrogate p38α/β-driven cytokine biology while preserving much of the broader T-cell response. This article connects its established TNF-alpha phenotype with emerging evidence that kinase conformation can influence phosphatase-driven signal termination, creating a more rigorous framework for inflammatory disease research.

• Telatinib Workflow for Angiogenesis Research

  2026-09-08

  Telatinib (BAY 57-9352) supports mechanism-aware studies that connect receptor kinase inhibition with tumor-cell invasion and endothelial tube formation. This workflow emphasizes dosing discipline, target attribution, combination analysis, and troubleshooting beyond a simple viability readout.

• Measuring Drug Response Beyond Viability Assays

  2026-09-07

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to separate proliferative arrest from actual cell killing in cancer drug studies. Its central implication is that time-resolved, multidimensional response measurements can improve interpretation of anticancer compound activity beyond a single viability value.

• Chlorambucil: Interpreting DNA Damage Assays

  2026-09-07

  Chlorambucil is a nitrogen mustard alkylating agent whose delayed DNA damage can produce very different viability and cell-death readouts. This guide applies evidence from Schwartz’s cancer-assay research to build a more rigorous, time-resolved framework for interpreting chlorambucil experiments.

• Firefly Luciferase mRNA: Workflow & Optimization

  2026-09-05

  Build more interpretable gene expression, cell viability, and delivery studies with a capped, 5-moU-modified bioluminescent reporter. This practical guide connects assay setup with the metal-mediated mRNA enrichment strategy reported in Nature Communications, while separating product performance from formulation effects.

588 records 7/40 page Previous Next First page 上5页 678910 下5页 Last page